Monday, October 10, 2011 7:47:54 AM
Thanks for the feedback and link (not rkrw's I don't like to think about that 
). It seems there was some concern of anaphylaxis though in practice it doesn't seem to be a major concern. The IP is one things that has me concerned they claim they have patents till 2028. The wording in the auxilium's annual report isn't clear but I believe they are process related patents. Also in Europe they don't even have orphan protection (at least for Dupuytren’s)!
). It seems there was some concern of anaphylaxis though in practice it doesn't seem to be a major concern. The IP is one things that has me concerned they claim they have patents till 2028. The wording in the auxilium's annual report isn't clear but I believe they are process related patents. Also in Europe they don't even have orphan protection (at least for Dupuytren’s)!
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
